207 related articles for article (PubMed ID: 8935803)
1. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.
Bymaster FP; Hemrick-Luecke SK; Perry KW; Fuller RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):87-94. PubMed ID: 8935803
[TBL] [Abstract][Full Text] [Related]
2. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.
Zhang W; Bymaster FP
Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508
[TBL] [Abstract][Full Text] [Related]
3. Effects of atypical antipsychotic drugs on dopamine output in the shell and core of the nucleus accumbens: role of 5-HT(2A) and alpha(1)-adrenoceptor antagonism.
Marcus MM; Nomikos GG; Svensson TH
Eur Neuropsychopharmacol; 2000 Jul; 10(4):245-53. PubMed ID: 10871706
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate.
Fuller RW; Snoddy HD
Res Commun Chem Pathol Pharmacol; 1992 Jul; 77(1):87-93. PubMed ID: 1359615
[TBL] [Abstract][Full Text] [Related]
5. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Adhumeau A; Brocco M; Nicolas JP; Boutin JA; Despaux N; Peglion JL
J Pharmacol Exp Ther; 2000 Jan; 292(1):38-53. PubMed ID: 10604930
[TBL] [Abstract][Full Text] [Related]
6. Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro.
Bymaster FP; Nelson DL; DeLapp NW; Falcone JF; Eckols K; Truex LL; Foreman MM; Lucaites VL; Calligaro DO
Schizophr Res; 1999 May; 37(1):107-22. PubMed ID: 10227113
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.
Li XM; Perry KW; Wong DT; Bymaster FP
Psychopharmacology (Berl); 1998 Mar; 136(2):153-61. PubMed ID: 9551772
[TBL] [Abstract][Full Text] [Related]
8. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.
Volonté M; Monferini E; Cerutti M; Fodritto F; Borsini F
J Neurochem; 1997 Jul; 69(1):182-90. PubMed ID: 9202309
[TBL] [Abstract][Full Text] [Related]
9. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens.
Ichikawa J; Kuroki T; Dai J; Meltzer HY
Eur J Pharmacol; 1998 Jun; 351(2):163-71. PubMed ID: 9686999
[TBL] [Abstract][Full Text] [Related]
10. Clozapine-induced dopamine levels in the rat striatum and nucleus accumbens are not affected by muscarinic antagonism.
Gray AM; Connick JH
Eur J Pharmacol; 1998 Dec; 362(2-3):127-36. PubMed ID: 9874162
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
Bymaster FP; Rasmussen K; Calligaro DO; Nelson DL; DeLapp NW; Wong DT; Moore NA
J Clin Psychiatry; 1997; 58 Suppl 10():28-36. PubMed ID: 9265914
[TBL] [Abstract][Full Text] [Related]
12. Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum.
Dean B; Hussain T; Scarr E; Pavey G; Copolov DL
Life Sci; 2001 Aug; 69(11):1257-68. PubMed ID: 11521750
[TBL] [Abstract][Full Text] [Related]
13. Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Ichikawa J; Chung YC; Li Z; Dai J; Meltzer HY
Brain Res; 2002 Dec; 958(1):176-84. PubMed ID: 12468043
[TBL] [Abstract][Full Text] [Related]
14. Effect of olanzapine on functional responses from sensitized D1-dopamine receptors in rats with neonatal dopamine loss.
Moy SS; Knapp DJ; Breese GR
Neuropsychopharmacology; 2001 Aug; 25(2):224-33. PubMed ID: 11425506
[TBL] [Abstract][Full Text] [Related]
15. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine: a basic science update.
Bymaster F; Perry KW; Nelson DL; Wong DT; Rasmussen K; Moore NA; Calligaro DO
Br J Psychiatry Suppl; 1999; (37):36-40. PubMed ID: 10211140
[TBL] [Abstract][Full Text] [Related]
17. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.
Gleason SD; Shannon HE
Psychopharmacology (Berl); 1997 Jan; 129(1):79-84. PubMed ID: 9122367
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
[TBL] [Abstract][Full Text] [Related]
19. Dopamine D(3) receptors modulate evoked dopamine release from slices of rat nucleus accumbens via muscarinic receptors, but not from the striatum.
Yamada S; Harano M; Annoh N; Tanaka M
J Pharmacol Exp Ther; 1999 Dec; 291(3):994-8. PubMed ID: 10565816
[TBL] [Abstract][Full Text] [Related]
20. Radioreceptor binding profile of the atypical antipsychotic olanzapine.
Bymaster FP; Calligaro DO; Falcone JF; Marsh RD; Moore NA; Tye NC; Seeman P; Wong DT
Neuropsychopharmacology; 1996 Feb; 14(2):87-96. PubMed ID: 8822531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
